Key Highlights

Risk & Performance

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

N/A

1(100.0%)

1Total

N/A(1)

Loading network data...

Showing 6 of 6 trials

Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esophagogastric Junction Cancer

Role: lead

Influence of Age on the Choice of Treatment and Prognosis in Patients With Resectable Gastric Cancer

Role: lead

Morbidity and Mortality After Esophageal and Esophagogastric Junction Cancer Surgery

Role: lead

Neoadjuvant FOLFOX Chemotherapy for Colon Cancer: Long-Term Chemotherapy-Induced Peripheral Neuropathy and Impact on Quality of Life

Role: lead

Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer

Role: collaborator

Postoperative Morbidity and Mortality After Gastric Cancer Surgery

Role: lead

All 6 trials loaded